Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
28.89
+0.06 (0.21%)
At close: Nov 13, 2026, 4:00 PM EST
28.91
+0.02 (0.07%)
After-hours: Nov 13, 2026, 7:59 PM EST
Pfizer Revenue
Pfizer had revenue of $16.58B in the quarter ending September 27, 2026, a decrease of -0.43%. This brings the company's total for the last twelve months to $63.63B, up 1.34% year-over-year. In the year 2025, Pfizer had annual revenue of $62.58B, down -1.65%. That makes Pfizer the 193rd largest company in the world by revenue and 79th in the United States.
Revenue (ttm)
$63.63B
Revenue Growth
+1.34%
P/S Ratio
2.59
Revenue / Employee
$848,320
Employees
75,000
Market Cap
164.67B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Pfizer breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.58B | -1.05B | -1.65% |
| Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
| Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
| Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
| Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
| Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
| Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
| Dec 31, 2018 | 40.83B | -11.72B | -22.31% |
| Dec 31, 2017 | 52.55B | -278.00M | -0.53% |
| Dec 31, 2016 | 52.82B | 3.97B | 8.13% |
| Dec 31, 2015 | 48.85B | -754.00M | -1.52% |
| Dec 31, 2014 | 49.61B | -1.98B | -3.84% |
| Dec 31, 2013 | 51.58B | -3.07B | -5.62% |
| Dec 31, 2012 | 54.66B | -6.38B | -10.45% |
| Dec 31, 2011 | 61.04B | -4.13B | -6.34% |
| Dec 31, 2010 | 65.17B | 15.90B | 32.26% |
| Dec 31, 2009 | 49.27B | 973.00M | 2.01% |
| Dec 31, 2008 | 48.30B | -122.00M | -0.25% |
| Dec 31, 2007 | 48.42B | 47.00M | 0.10% |
| Dec 31, 2006 | 48.37B | 966.00M | 2.04% |
| Dec 31, 2005 | 47.41B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 99.34B |
| Merck & Co. | 67.38B |
| AbbVie | 66.01B |
| AstraZeneca | 62.38B |
| Sanofi | 57.89B |
| Novartis AG | 57.36B |
| Novo Nordisk | 50.70B |
| Bristol-Myers Squibb Company | 50.03B |
PFE News
- 3 days ago - Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug - Barrons
- 3 days ago - Pfizer now sees 2026 adjusted EPS $1.45-$1.54, consensus $2.00 - TheFly
- 3 days ago - Pfizer Slides: Investor presentation - Filings
- 4 days ago - Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development - WSJ
- 4 days ago - Pfizer secures up to $1.5 billion from Blackstone for obesity drug development - Reuters
- 4 days ago - Pfizer, Blackstone Life Sciences announce strategic co-funding agreement - TheFly
- 4 days ago - Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program - Business Wire
- 5 days ago - Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - Business Wire